RE:RE:Commercialization phase - Jan 2023 to December 2025Eoganacht ... Yep!
Rights to Ph. 2b data is worth approx. 900MM$, more or less. So we will receive an upfront payment that will be used to move forward more indications (COVID-19, NSCLC, etc ...), with the support of the Li Ka Shing Institute.
Valuation is around the corner. No doubt.
A Breakthrough designation is worth something very valuable. Just ike a only 2-doses treatment with no side-effects, that destroys solid tumors instantly and that can save, for an indication that has a high rate of recurrence.